Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Phathom Pharmaceuticals Inc PHAT

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:PHAT)

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2024

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"

GlobeNewswire March 26, 2024

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 7, 2024

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

GlobeNewswire February 29, 2024

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

GlobeNewswire February 13, 2024

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire January 31, 2024

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

GlobeNewswire December 14, 2023

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

GlobeNewswire December 6, 2023

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

GlobeNewswire November 28, 2023

Opinion & Analysis (NDAQ:PHAT)

No current opinion is available.

Bullboard Posts (NDAQ:PHAT)

5 BIOTECH STOCKS WITH MAJOR UPCOMING CATALYSTS

$PHAT $CYTK $ADGI $AGIO $ICPT   Clinical-Stage companies offer an exciting investment opportunity with massive upside potential...
AviseAnalytics - February 8, 2022

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021